Şunu aradınız:: populationsfarmakokinetik (Danca - İngilizce)

populationsfarmakokinetik
population pharmacokinetics

særlige populationer populationsfarmakokinetik
special populations

siltuximabs populationsfarmakokinetik blev analyseret for at evaluere virkningerne af demografiske kendetegn.
the population pk of siltuximab were analysed to evaluate the effects of demographic characteristics.

baseret på en analyse af populationsfarmakokinetik, har alder en ringe indflydelse på regadenosons farmakokinetik.
based on a population pharmacokinetic analysis, age has a minor influence on the pharmacokinetics of regadenoson.

populationsfarmakokinetik indikerede, at alder ikke har signifikant indflydelse på ibrutinib-clearance fra kredsløbet.
population pharmacokinetics indicated that age does not significantly influence ibrutinib clearance from the circulation.

imidlertid er forholdet mellem nyrefunktion og tolcapons farmakokinetik blevet undersøgt ved anvendelse af populationsfarmakokinetik i kliniske undersøgelser.
however, the relationship of renal function and tolcapone pharmacokinetics has been investigated using population pharmacokinetics during clinical trials.

imidlertid er forholdet mellem nyrefunktion og tolcapons farmakokinetik blevet undersøgt ved anvendelse af populationsfarmakokinetik i kliniske undersøgelser.data fra flere end
however, the relationship of renal function and tolcapone pharmacokinetics has been investigated using population pharmacokinetics during clinical trials.

der blev ikke identificeret noget klart forhold mellem nyrefunktion (målt ved kreatininclearance) og granisetronclearance i modeller af populationsfarmakokinetik.
no clear relationship between renal function (as measured by creatinine clearance) and granisetron clearance was identified in population pk modelling.

på basis af en analyse af populationsfarmakokinetik og ranibizumabs forsvinden fra serum for patienter behandlet med dosen på 0, 5 mg er den gennemsnitlige corpus vitreum -eliminationshalveringstid for ranibizumab ca.
based on analysis of population pharmacokinetics and disappearance of ranibizumab from serum for patients treated with the 0.5 mg dose, the average vitreous elimination half-life of ranibizumab is

kuvans sikkerhed, virkning og populationsfarmakokinetik blev undersøgt i et åbent, randomiseret kontrolleret multicenterstudie hos børn <4 år med en bekræftet pku-diagnose.
the safety, efficacy and population pharmacokinetics of kuvan were studied in a multicentre, open-label, randomised, controlled study in children <4 years old with a confirmed diagnosis of pku.

populationsfarmakokinetik hos patienter med pulmonal arteriel hypertension er de gennemsnitlige steady state koncentrationer 20-50% højere end de undersøgte doser på 20-80 mg 3 gange dagligt sammenlignet med raske frivillige forsøgspersoner.
population pharmacokinetics:in patients with pulmonary arterial hypertension, the average steady state concentrations were 20 ­ 50% higher over the investigated dose range of 20­80 mg three times a day compared to healthy volunteers.

på baggrund af en analyse af populationsfarmakokinetikken for patienter mellem 19 - 78 år er tmz- clearance ikke afhængig af alder.
based on a population pharmacokinetic analysis in patients 19 – 78 years of age, clearance of tmz is not affected by age.